Login to Your Account

United Skies Unfriendly After Treprostinil Flunks Oral Exam

By Randy Osborne
Staff Writer

Wednesday, October 24, 2012
United Therapeutics Inc. will stay in hunker-down mode for the next few months, as the company works to puzzle out exactly what the FDA wants, in the wake of a complete response letter that found the data package unacceptable in the new drug application for oral treprostinil in pulmonary arterial hypertension (PAH).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription